Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018218357) METHODS FOR DIAGNOSING AND TREATING CACHEXIA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/218357 International Application No.: PCT/CA2018/050639
Publication Date: 06.12.2018 International Filing Date: 30.05.2018
IPC:
A61K 31/603 (2006.01) ,A61K 31/194 (2006.01) ,A61K 31/616 (2006.01) ,C07C 65/105 (2006.01) ,C07C 66/00 (2006.01) ,C07C 69/145 (2006.01) ,G01N 33/48 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
60
Salicylic acid; Derivatives thereof
603
having further aromatic rings, e.g. diflunisal
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
194
having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
60
Salicylic acid; Derivatives thereof
612
having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
616
by carboxylic acids, e.g. acetylsalicylic acid
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
65
Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, -CHO, keto, ether, groups, groups, or groups
01
containing hydroxy or O-metal groups
105
polycyclic
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
66
Quinone carboxylic acids
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
69
Esters of carboxylic acids; Esters of carbonic or haloformic acids
02
Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
12
Acetic acid esters
14
of monohydroxylic compounds
145
of unsaturated alcohols
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
Applicants:
AURIN BIOTECH INC. [CA/CA]; 4727 West 2nd Avenue Vancouver, British Columbia V6T 1C1, CA
Inventors:
MCGEER, Patrick L.; CA
LEE, Moonhee; CA
MCGEER, Edith G.; CA
KENNEDY, Krista; CA
Agent:
TAKAGAWA, David H.; CA
Priority Data:
62/513,27731.05.2017US
Title (EN) METHODS FOR DIAGNOSING AND TREATING CACHEXIA
(FR) MÉTHODES DE DIAGNOSTIC ET DE TRAITEMENT DE LA CACHEXIE
Abstract:
(EN) A method of treating cachexia is provided. The method includes administering to a human in need thereof an effective amount of a complement inhibitor. The complement inhibitor may be a dimer of acetyl salicylic acid, including 5,5'-methylenebis(2-hydroxybenzoic acid), 4,4'-diacetoxy-1,1 biphenyl-3,3' dicarboxylic acid or a pharmaceutically acceptable salt thereof. The complement inhibitor may be aurin tricarboxylic acid, aurin quadracarboxylic acid, aurin pentacarboxylic acid, aurin hexacarboxylic acid, combinations thereof, and pharmaceutically acceptable salts thereof. The complement inhibitor may be an ester prodrug of the foregoing compounds.
(FR) L'invention porte sur une méthode de traitement de la cachexie. La méthode comprend l'administration à un être humain en ayant besoin d'une quantité efficace d'un inhibiteur du complément. L'inhibiteur du complément peut être un dimère d'acide acétyl salicylique, y compris l'acide 5,5'-méthylènebis(acide 2-hydroxybenzoïque), 4,4'-diacétoxy-1,1 biphényl-3,3' dicarboxylique ou un sel pharmaceutiquement acceptable de celui-ci. L'inhibiteur du complément peut être de l'acide aurine tricarboxylique, de l'acide aurine quadracarboxylique, de l'acide aurine pentacarboxylique, de l'acide aurine hexacarboxylique, des combinaisons de ceux-ci, et des sels pharmaceutiquement acceptables de ceux-ci. L'inhibiteur du complément peut être un promédicament ester des composés précédents.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)